James Turvill1, Daniel Turnock2, Hayden Holmes3, Alison Jones2, Eleanor Mclaughlan4, Victoria Hilton5, Stacey Marriott6. 1. Department of Gastroenterology, York Hospital, York Teaching Hospital NHS Foundation Trust, York, North Yorkshire, UK. 2. Department of Clinical Biochemistry, York Teaching Hospital NHS Foundation Trust, York, North Yorkshire, UK. 3. York Health Economics Consortium Ltd, York, North Yorkshire, UK. 4. Department of Blood Sciences, Old Medical School, Leeds General Infirmary, Leeds, UK. 5. Yorkshire and Humber Academic Health Sciences Network, Wakefield, UK. 6. NHS Vale of York Clinical Commissioning Group, York, UK.
Abstract
OBJECTIVE: To evaluate the sensitivity and specificity of the York Faecal Calprotectin Care Pathway (YFCCP) and undertake a health economics analysis. The YFCCP has been introduced in support of the National Institute for Health and Care Excellence (NICE) guidance DG11. It is designed to improve the sensitivity and specificity of faecal calprotectin (FC) in discriminating the irritable bowel syndrome from inflammatory bowel disease in primary care. DESIGN: To prospectively evaluate the clinical outcomes at 6 months of the first 1005 patients entering the YFCCP. To develop a cost-consequence model using two comparators: one based on clinical assessment and the C reactive protein/erythrocyte sedimentation rate without using FC, and the second using single testing of the standard FC cut-off. SETTING: North Yorkshire primary care practices. PATIENTS: Primary care patients fulfilling NICE DG11. INTERVENTIONS: The YFCCP. MAIN OUTCOME MEASURES: Clinical outcome measures from secondary care records. RESULTS: The sensitivity and specificity of the YFCCP are 0.94 (0.85 to 0.98) and 0.92 (0.90 to 0.94), giving a negative and positive predictive value of 0.99 (0.98 to 1.0) and 0.51 (0.43 to 0.59), respectively. CONCLUSIONS: The YFCCP overcomes the challenges experienced with FC use in primary care, its efficacy matching initial NICE projections. It is readily incorporated into clinical practice. It should represent the framework on which to increase NICE DG11 implementation nationally.
OBJECTIVE: To evaluate the sensitivity and specificity of the York Faecal Calprotectin Care Pathway (YFCCP) and undertake a health economics analysis. The YFCCP has been introduced in support of the National Institute for Health and Care Excellence (NICE) guidance DG11. It is designed to improve the sensitivity and specificity of faecal calprotectin (FC) in discriminating the irritable bowel syndrome from inflammatory bowel disease in primary care. DESIGN: To prospectively evaluate the clinical outcomes at 6 months of the first 1005 patients entering the YFCCP. To develop a cost-consequence model using two comparators: one based on clinical assessment and the C reactive protein/erythrocyte sedimentation rate without using FC, and the second using single testing of the standard FC cut-off. SETTING: North Yorkshire primary care practices. PATIENTS: Primary care patients fulfilling NICE DG11. INTERVENTIONS: The YFCCP. MAIN OUTCOME MEASURES: Clinical outcome measures from secondary care records. RESULTS: The sensitivity and specificity of the YFCCP are 0.94 (0.85 to 0.98) and 0.92 (0.90 to 0.94), giving a negative and positive predictive value of 0.99 (0.98 to 1.0) and 0.51 (0.43 to 0.59), respectively. CONCLUSIONS: The YFCCP overcomes the challenges experienced with FC use in primary care, its efficacy matching initial NICE projections. It is readily incorporated into clinical practice. It should represent the framework on which to increase NICE DG11 implementation nationally.
Entities:
Keywords:
Ibd; clinical decision making; general practice; irritable bowel syndrome
Authors: Delphine Labaere; Annick Smismans; August Van Olmen; Paul Christiaens; Geert D'Haens; Veerle Moons; Pieter-Jan Cuyle; Johan Frans; Peter Bossuyt Journal: United European Gastroenterol J Date: 2014-02 Impact factor: 4.623
Authors: James Turvill; Shaun O'Connell; Abigail Brooks; Karen Bradley-Wood; James Laing; Swaminathan Thiagarajan; David Hammond; Daniel Turnock; Alison Jones; Ruchit Sood; Alex Ford Journal: Prim Health Care Res Dev Date: 2016-02-22 Impact factor: 1.458
Authors: Alexander C von Roon; Leonidas Karamountzos; Sanjay Purkayastha; George E Reese; Ara W Darzi; Julian P Teare; Paraskevas Paraskeva; Paris P Tekkis Journal: Am J Gastroenterol Date: 2007-02-23 Impact factor: 10.864
Authors: N Waugh; E Cummins; P Royle; N-B Kandala; D Shyangdan; R Arasaradnam; C Clar; R Johnston Journal: Health Technol Assess Date: 2013-11 Impact factor: 4.014
Authors: Jeremy A Tibble; Gudmundur Sigthorsson; Russell Foster; Ian Forgacs; Ingvar Bjarnason Journal: Gastroenterology Date: 2002-08 Impact factor: 22.682
Authors: P Jellema; M W van Tulder; H E van der Horst; J Florie; C J Mulder; D A W M van der Windt Journal: Colorectal Dis Date: 2011-03 Impact factor: 3.788
Authors: Nicholas A Kennedy; Annalie Clark; Andrew Walkden; Jeff C W Chang; Federica Fascí-Spurio; Martina Muscat; Brydon W Gordon; Kathleen Kingstone; Jack Satsangi; Ian D R Arnott; Charlie W Lees Journal: J Crohns Colitis Date: 2015-01 Impact factor: 9.071
Authors: Christopher Andrew Lamb; Nicholas A Kennedy; Tim Raine; Philip Anthony Hendy; Philip J Smith; Jimmy K Limdi; Bu'Hussain Hayee; Miranda C E Lomer; Gareth C Parkes; Christian Selinger; Kevin J Barrett; R Justin Davies; Cathy Bennett; Stuart Gittens; Malcolm G Dunlop; Omar Faiz; Aileen Fraser; Vikki Garrick; Paul D Johnston; Miles Parkes; Jeremy Sanderson; Helen Terry; Daniel R Gaya; Tariq H Iqbal; Stuart A Taylor; Melissa Smith; Matthew Brookes; Richard Hansen; A Barney Hawthorne Journal: Gut Date: 2019-09-27 Impact factor: 23.059
Authors: Karoline Freeman; Brian H Willis; Ronan Ryan; Sian Taylor-Phillips; Aileen Clarke Journal: BMC Med Res Methodol Date: 2022-07-12 Impact factor: 4.612
Authors: Alan Lobo; Rafael Torrejon Torres; Mark McAlindon; Simon Panter; Catherine Leonard; Nancy van Lent; Rhodri Saunders Journal: Int J Qual Health Care Date: 2020-06-17 Impact factor: 2.038